Core Viewpoint - BrainStorm Cell Therapeutics Inc. is making significant progress in the development of its NurOwn® therapy for ALS, with plans for a Phase 3b trial aimed at confirming efficacy in early-stage ALS patients and supporting a new Biologics License Application (BLA) [2][4]. Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and restricted cash of approximately $1.8 million [4]. - Research and development expenditures for Q1 2025 were $1.3 million, an increase from $1.0 million in Q1 2024 [4]. - General and administrative expenses for Q1 2025 were approximately $1.8 million, compared to $1.5 million in Q1 2024 [4]. - The net loss for Q1 2025 was approximately $2.9 million, an improvement from a net loss of approximately $3.4 million in Q1 2024 [4][14]. - Net loss per share for Q1 2025 was $0.45, compared to $0.75 for Q1 2024 [4][14]. Corporate Updates - The company submitted an IND amendment for NurOwn to the FDA, which is a critical step for the upcoming Phase 3b trial [4]. - The Phase 3b trial, named ENDURANCE, is designed to enroll approximately 200 early-stage ALS participants and will assess changes in ALSFRS-R scores [4]. - NurOwn data was selected for presentation at the ISCT 2025 Meeting, highlighting the impact of the UNC13A genotype on clinical outcomes for ALS patients [4]. - Insights on biomarkers related to NurOwn treatment were presented at the 2025 ALS Drug Development Summit [4]. About NurOwn® - NurOwn® is an investigational therapy utilizing autologous MSC-NTF cells, which are derived from bone marrow and designed to deliver neurotrophic factors to slow or stabilize neurodegenerative diseases [6][8]. - The therapy has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial has been completed [8]. Company Overview - BrainStorm Cell Therapeutics Inc. focuses on developing autologous adult stem cell therapies for neurodegenerative diseases, with its proprietary NurOwn® platform aimed at modulating neuroinflammation and promoting neuroprotection [7].

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has rescheduled the release of its financial results for Q1 2025 and an investor conference call, indicating ongoing engagement with investors and stakeholders [1][2]. Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of adult stem cell therapies targeting neurodegenerative diseases, utilizing its proprietary NurOwn® platform to produce neurotrophic factor-secreting cells [5]. - The company's lead investigational therapy, NurOwn®, has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial for ALS has been completed [6]. Upcoming Events - The financial results will be released post-market on May 15, 2025, and the investor conference call is scheduled for May 19, 2025, at 8:30 a.m. Eastern Time [1][2]. - Participants are encouraged to submit questions in advance, with specific contact details provided for access to the conference call [3]. Clinical Development - BrainStorm has completed a Phase 2 trial of MSC-NTF cells in progressive multiple sclerosis, supported by a grant from the National MS Society [6]. - The company is advancing an allogeneic exosome-based platform for delivering therapeutic proteins and nucleic acids, with a foundational patent recently allowed by the U.S. Patent and Trademark Office [6].

Company Overview - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of adult stem cell therapeutics aimed at treating neurodegenerative diseases [3][4] - The company's proprietary NurOwn® platform utilizes autologous mesenchymal stem cells (MSCs) to create neurotrophic factor-secreting cells (MSC-NTF cells) [3][4] Upcoming Conference Call - A conference call is scheduled for May 15, 2025, at 8:30 a.m. Eastern Time to discuss the financial results for Q1 2025 and provide a corporate update [1][2] - The call will feature BrainStorm's President & CEO Chaim Lebovits, along with Dr. Bob Dagher, Chief Medical Officer, and Alla Patlis, Interim CFO [2] Clinical Development - NurOwn® is the lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the FDA and EMA [4] - A Phase 3 trial for ALS has been completed, and a confirmatory Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA [4] - The clinical program has provided insights into ALS disease biology, including pharmacogenomic responses and biomarker data [4] Additional Research and Development - BrainStorm has completed a Phase 2 open-label multicenter trial of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society [4] - The company is also advancing an allogeneic exosome-based platform for delivering therapeutic proteins and nucleic acids, with a foundational patent recently allowed by the U.S. Patent and Trademark Office [4]

Core Insights - BrainStorm Cell Therapeutics Inc. is participating in the 4th Annual ALS Drug Development Summit, showcasing its expertise in ALS clinical research and the NurOwn® development program [1][5] Company Developments - Netta Blondheim-Shraga, PhD, will present new insights into cerebrospinal fluid biomarker pathways related to Debamestrocel (NurOwn), focusing on their connection to clinical outcomes and disease heterogeneity in ALS [2] - The company is preparing to launch its Phase 3b clinical trial of NurOwn, which has received a Special Protocol Assessment (SPA) from the FDA, indicating that the trial's design is adequate for future marketing application if successful [5] - Dr. Bob Dagher will moderate a workshop on adaptive and decentralized clinical trial models aimed at improving enrollment and reducing the burden on ALS patients [3][4] Research and Development - Biomarker data from a prior Phase 3 study suggests a multimodal mechanism of action for NurOwn, enhancing understanding of its influence on ALS disease pathways [3] - The upcoming Phase 3b trial will refine patient selection criteria and trial design based on learnings from previous studies [4] - The NurOwn clinical program has provided valuable insights into ALS biology, including pharmacogenomic responses and biomarker data collected over time [6] Industry Context - A panel discussion will address the role of patient and caregiver engagement in clinical trials and the impact of the diagnostic journey on trial decision-making [4] - The company is advancing a proprietary exosome-based platform for therapeutic delivery, further strengthening its intellectual property portfolio in regenerative medicine [8]

Core Insights - New pharmacogenomic data on the impact of the UNC13A genotype on treatment response in ALS patients treated with NurOwn® will be presented at the ISCT 2025 Annual Meeting [1][2] - The findings are significant as they may help predict treatment responses based on genetic factors, advancing personalized medicine for ALS [2][3] Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases, with its proprietary NurOwn® platform utilizing mesenchymal stem cells to produce neurotrophic factor-secreting cells [4][5] - NurOwn® has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial in ALS has been completed, with a confirmatory Phase 3b trial set to launch under a Special Protocol Assessment agreement with the FDA [5][6] Clinical Development - The upcoming Phase 3b trial aims to build on existing clinical data and demonstrate NurOwn's potential in early ALS, with positive communication ongoing with the FDA [3][5] - The recent findings provide insights into treatment effects in patient subpopulations and represent a first-of-its-kind pharmacogenomic analysis in ALS, focusing on how genetic differences affect therapy response [3][6] Presentation Details - The oral presentation titled "Debamestrocel Effect on Clinical and Biomarker Endpoints by UNC13A Genotype in Phase 3 ALS Trial" will take place on May 8, 2025, at the ISCT meeting in New Orleans [3]

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has submitted an Investigational New Drug (IND) amendment for NurOwn®, an autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS), paving the way for a Phase 3b clinical trial in collaboration with the FDA under a Special Protocol Assessment (SPA) [1][2] Group 1: IND Submission and Trial Design - The IND amendment submission and FDA's agreement on the trial design under the SPA represent a significant advancement towards making NurOwn available to ALS patients [2] - The Phase 3b trial will enroll approximately 200 ALS participants and will consist of two parts: a 24-week double-blind period followed by an open-label extension [2] - The primary efficacy endpoint will evaluate changes in ALSFRS-R scores from baseline to week 24, comparing the disease progression between NurOwn and placebo groups [2] Group 2: NurOwn Technology and Company Background - NurOwn® technology involves autologous MSC-NTF cells derived from bone marrow, designed to deliver neurotrophic factors and immunomodulatory cytokines to slow or stabilize disease progression in neurodegenerative disorders [4] - BrainStorm Cell Therapeutics is a leading developer of autologous adult stem cell therapeutics for neurodegenerative diseases and holds exclusive rights to the NurOwn® technology platform [5] - The company has received Orphan Drug designation from the FDA and EMA for ALS treatment and has completed a Phase 3 pivotal trial investigating the safety and efficacy of autologous MSC-NTF cells [5]

Financial Data and Key Metrics Changes - Research and development expenditures for the year ended December 31, 2024, were approximately $4.7 million, a decrease from $10.7 million in 2023 [22] - General and administrative expenses for the same period were about $7 million, down from $10.7 million in 2023 [22] - The net loss for the year ended December 31, 2024, was approximately $11.6 million, or $2.31 per share, compared to a net loss of approximately $17.2 million, or $6 per share, for 2023 [22][23] - Cash equivalents and restricted cash were approximately $0.4 million at the end of December 2024, down from $1.5 million at the end of December 2023 [23] Business Line Data and Key Metrics Changes - The company is focused on advancing the Phase 3B trial of Neuron, its investigational treatment for ALS, with preparations for patient enrollment underway [7][8] - The company has established partnerships with leading clinical centers and a clinical research organization to support trial execution [12][13] Market Data and Key Metrics Changes - The company is actively pursuing multiple funding avenues, including licensing non-core assets and exploring non-dilutive financing opportunities such as grants [15][34] - The anticipated funding requirement for the trial is approximately $20-30 million annually, with a focus on achieving key milestones to improve market valuation [18][35] Company Strategy and Development Direction - The primary focus for 2025 is on clear execution of the Phase 3B trial, with a strong belief in Neuron's potential to significantly impact ALS patients [8][20] - The company is committed to transparency and rigorous regulatory processes, emphasizing the importance of robust data to validate Neuron's efficacy [17][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the urgency and frustration regarding trial timelines but emphasizes the complexity of regulatory processes as a reason for perceived delays [29] - The company is confident in its ability to navigate financial challenges and is committed to ensuring that the team's dedication will be recognized as milestones are achieved [51] Other Important Information - The company has entered into a warrant-inducing agreement expected to raise approximately $1.64 million in gross proceeds [23] - Management has implemented cost-saving measures, including salary reductions, to prioritize the trial's progress [50] Q&A Session Summary Question: Concerns about delays in initiating the Phase 3B trial - Management understands the frustration regarding the trial timeline, attributing delays to the complexity of regulatory processes and negotiations with clinical sites [29][30] Question: Financial situation and funding plans - The company is actively pursuing multiple funding avenues, including a recent warrant inducement agreement and exploring non-dilutive financing through grants [34][35] Question: Addressing skepticism about Neuron's efficacy - Management acknowledges skepticism but emphasizes the strong support from key opinion leaders and the commitment to providing robust data to validate Neuron's potential [41][42] Question: Status of manufacturing facilities - The company has contracted with a clinical manufacturing partner and is planning to establish a U.S.-based manufacturing center to ensure a consistent supply of Neuron [46] Question: Ensuring operational continuity amid financial constraints - Management has implemented strategic cost-saving measures and remains focused on advancing the trial despite financial challenges [50][51] Question: Why not refile the original BLA - Management believes that generating robust data through the Phase IIIb trial is the most strategic path forward to address specific concerns raised previously [53]

Clinical Trials and Regulatory Status - NurOwn® has completed Phase 3 ALS and Phase 2 PMS clinical trials, with positive top-line data announced on March 24, 2021, for PMS[14]. - The FDA granted a Special Protocol Assessment (SPA) agreement on April 9, 2024, validating the Phase 3b trial design for NurOwn® in ALS[15]. - The FDA's Advisory Committee voted on September 27, 2023, with 17 voting no, indicating that NurOwn® did not demonstrate substantial evidence of effectiveness for mild to moderate ALS[14]. - The BLA for NurOwn® was withdrawn on November 3, 2023, in coordination with the FDA, viewed as a withdrawal without prejudice[14]. - The Phase 3 clinical trial for NurOwn® in ALS did not achieve statistically significant results, with 32.6% of participants meeting the primary endpoint compared to 27.7% for placebo (p=0.453)[47]. - The average change in ALSFRS-R total score from baseline to Week 28 was -5.52 for NurOwn® versus -5.88 for placebo, showing a difference of 0.36 (p=0.693)[47]. - In a pre-specified subgroup with ALSFRS-R baseline scores of 35 or greater, NurOwn® demonstrated a 34.6% responder rate compared to 15.6% for placebo (p=0.305)[47]. - The FDA issued a Refusal to File (RTF) letter on November 10, 2022, stating that the BLA was not sufficiently complete for substantive review, citing issues related to evidence of effectiveness and CMC items[49]. - Following a Type A meeting with the FDA on January 11, 2023, the company requested to file the BLA over Protest on February 6, 2023, which was confirmed by the FDA on February 7, 2023[50]. - An amendment to the BLA was submitted on March 7, 2023, addressing most items in the RTF letter, and the FDA confirmed an Advisory Committee (ADCOM) meeting for the BLA on March 27, 2023[52]. - The ADCOM meeting held on September 27, 2023, resulted in a vote of 17 no, 1 yes, and 1 abstention, indicating that NurOwn® did not demonstrate substantial evidence of effectiveness for mild to moderate ALS[52]. - The BLA for NurOwn® was officially withdrawn on November 3, 2023, in coordination with the FDA, and is considered a withdrawal without prejudice[64]. - A meeting with the FDA on December 6, 2023, focused on discussing plans for a Special Protocol Assessment (SPA) for a planned Phase 3b trial for NurOwn®[65]. - The SPA request for the Phase 3b clinical trial was submitted on February 23, 2024, and written agreement from the FDA was received on April 9, 2024, validating the trial protocol[65]. Manufacturing and Development - The NurOwn® manufacturing process includes harvesting stem cells from the patient's bone marrow and administering MSC-NTF cells intrathecally, which has been shown to be well tolerated[26]. - The company has developed a validated cryopreservation process for MSC, allowing multiple doses of NurOwn® from a single bone marrow harvest, enhancing manufacturing efficiency[53]. - As of November 1, 2023, the company optimized its manufacturing capabilities by leasing a GMP-certified cleanroom manufacturing center, significantly enhancing production capacity for NurOwn®[56]. - The company is actively engaged in research and development of NurOwn® and MSC-NTF derived Exosomes for various neurodegenerative disorders and ARDS, focusing on their unique ability to cross the blood-brain barrier[95]. - The company has improved the efficiency and stability of NurOwn® production, allowing centralized manufacturing and distribution to clinical trial sites[106]. - The company intends to establish fully-equipped cGMP-certified Cell-Processing Centers for NurOwn® production and distribution[203]. Financial and Operational Status - The company currently employs 29 employees, with a focus on recruiting and retaining talent to support the development of novel cell therapies[17]. - The company has not generated any operational revenues for the fiscal years ended December 31, 2021, 2022, 2023, or 2024[217]. - The company expects to incur substantial and increasing operating losses for the foreseeable future as it increases spending on development and commercialization efforts[217]. - The company will need to raise additional capital to fund its business objectives and operations, with no assurance that such funding will be available on favorable terms[212]. - The company has a history of losses and anticipates continuing to incur losses, which will adversely impact working capital, total assets, and stockholders' equity[217]. - The company faces risks related to compliance with Nasdaq listing requirements, which could affect stock price and liquidity[210]. - The company is subject to potential securities class action litigation and other stockholder litigation[210]. Intellectual Property and Market Position - The company has a strong intellectual property portfolio and has received Fast Track designation and Orphan Drug status from the FDA for ALS[16]. - The company holds approximately 30 granted patents and is expanding its portfolio to include exosome-based technologies[87]. - The company has a global patent portfolio protecting NurOwn® and exosome-based technology, covering key markets including the U.S., Europe, and Japan[121]. - The company maintains a commercial relationship with Ramot at Tel Aviv University under a Research and License Agreement, granting rights to certain intellectual property developed at the university[127]. - The Israeli subsidiary is required to pay royalties ranging from 3% to 5% of all net sales derived from the licensed intellectual property, and 20% to 25% on revenues from sublicensing[128]. Market and Regulatory Environment - The FDA's approval process for biological products includes multiple phases of clinical trials, with Phase 1 focusing on safety and dosage, Phase 2 on efficacy, and Phase 3 on broader patient populations[143]. - The FDA may issue a Complete Response Letter detailing deficiencies in the BLA, which could delay or refuse approval if regulatory criteria are not met[149]. - The approval process may involve inspections of manufacturing facilities to ensure compliance with cGMP and Good Clinical Practice (GCP) requirements[147]. - The FDA may grant orphan designation to drugs for rare diseases, providing benefits like grant funding and potential seven years of exclusivity upon first approval[152]. - The FDA's Fast Track designation allows for rolling review of marketing applications for products addressing serious conditions, expediting the approval process[155]. - The company intends to pursue regulatory approval for NurOwn® in the U.S., Europe, Japan, and Israel, which requires substantial time and financial resources[134]. - The company is aware of the potential impact of healthcare reform measures on future revenues and pricing pressures[201]. Research and Clinical Findings - Significant increases in neurotrophic factors and reductions in inflammatory markers were observed in cerebrospinal fluid samples post-treatment with NurOwn®[43]. - The Phase 2 study showed a slower rate of disease progression in ALS patients treated with NurOwn®, as measured by ALSFRS-R and Forced Vital Capacity[35]. - Key findings from the Phase 2 PMS trial included a 10% mean improvement in the timed 25-foot walk and a 4.8% improvement in the 9-hole peg test for NurOwn® treated patients[79]. - The company presented new biomarker data at the 3rd Annual ALS Drug Development Summit, suggesting ALS patients may benefit from longer-term treatment with NurOwn®[94]. - Preclinical studies showed that intratracheal administration of NurOwn® derived exosomes resulted in statistically significant improvements in lung parameters, including functional lung recovery and reduction in pro-inflammatory cytokines[98]. - The company presented compelling preclinical data demonstrating the potential of exosome-based technology in treating acute lung injuries and neurodegenerative diseases[112]. Legislative and Compliance Issues - The Act for ALS was signed into law on December 23, 2021, authorizing up to $100 million per year for five years, totaling $500 million for research on neurodegenerative diseases like ALS[157]. - The FDA's Action Plan for Rare Neurodegenerative Diseases, released on June 23, 2022, outlines a five-year strategy to enhance scientific achievement and innovation in ALS drug development[158]. - The FDA and NIH launched the Critical Path for Rare Neurodegenerative Diseases (CP-RND) on September 14, 2022, aimed at advancing understanding and treatment development for ALS[158]. - The federal Anti-Kickback Statute and False Claims Act impose significant compliance requirements on the company’s operations[179]. - The company may face penalties for non-compliance with price reporting metrics required by the government[176]. - The EU GDPR and UK GDPR impose strict data protection requirements that could lead to substantial fines for violations[183]. - Changes in governmental healthcare programs could significantly impact the success of the company's stem cell therapies[173]. Competitive Landscape - The ongoing Phase 3 trial for a competitor's ALS treatment has an estimated completion date of Q2 2026[204]. - Currently, there are four FDA-approved ALS therapies, each showing modest improvements in survival or ALS function[207].

Financial Performance - For the fiscal year ended December 31, 2024, BrainStorm reported a net loss of approximately $11.6 million, a decrease from a net loss of approximately $17.2 million in 2023, representing a 32% improvement[9]. - Research and development expenditures for 2024 were $4.7 million, down from $10.7 million in 2023, indicating a 56% reduction in R&D spending[9]. - General and administrative expenses decreased to approximately $7.0 million in 2024 from $10.7 million in 2023, reflecting a 35% reduction[9]. - Cash and cash equivalents were approximately $0.4 million as of December 31, 2024, down from $1.5 million at the end of 2023[9]. Clinical Trials and Partnerships - The company is preparing for a Phase 3b trial of NurOwn, which will involve approximately 200 participants with ALS, having secured a Special Protocol Assessment (SPA) agreement with the FDA[2]. - A strategic partnership with Pluri was announced to support manufacturing for the Phase 3b NurOwn trial, enhancing operational readiness[8]. Funding and Compliance - BrainStorm has entered into a warrant inducement agreement expected to raise approximately $1.64 million, anticipated to close on or about April 1, 2025[6]. - The company regained compliance with Nasdaq's minimum bid price requirement on October 30, 2024, ensuring continued listing on the Nasdaq Capital Market[8]. Intellectual Property and Research Findings - BrainStorm received a Notice of Allowance for a new patent covering exosome platform technology, strengthening its intellectual property portfolio[5]. - The company presented findings at the 2024 NEALS Meeting, showing a statistically significant survival benefit for ALS patients treated with NurOwn[8].

Core Insights - BrainStorm Cell Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2024, highlighting resilience and progress in developing therapies for neurodegenerative diseases, particularly ALS [2][7]. Financial Performance - Cash, cash equivalents, and short-term bank deposits were approximately $0.4 million as of December 31, 2024, down from $1.5 million as of December 31, 2023 [10]. - Research and development expenditures for the year were $4.7 million, a decrease from $10.7 million in 2023 [10][17]. - General and administrative expenses were approximately $7.0 million for 2024, compared to $10.7 million in 2023 [10][17]. - The net loss for the year was approximately $11.6 million, an improvement from a net loss of $17.2 million in 2023 [10][17]. - Net loss per share for 2024 was $2.31, compared to $6.00 in 2023 [10][17]. Corporate Developments - The company is preparing for a Phase 3b trial of NurOwn in ALS, with an agreement on a Special Protocol Assessment (SPA) from the FDA, which reduces regulatory risks [2]. - A new patent covering exosome platform technology was allowed by the U.S. Patent and Trademark Office, enhancing the company's intellectual property portfolio [5]. - A warrant inducement agreement is expected to raise approximately $1.64 million, closing around April 1, 2025 [6][10]. Clinical and Regulatory Updates - NurOwn technology, which utilizes autologous MSC-NTF cells, aims to target pathways in neurodegenerative disorders and has received Orphan Drug designation from the FDA and EMA for ALS treatment [12][13]. - The company has completed a Phase 3 pivotal trial in ALS and is actively working on the regulatory approval process for NurOwn [13].